A research on imaging of concentration of drug on the skin rash and normal skin tissue in patients with advanced pancreatic cancer treating with gemcitabine and erlotinib.

Trial Profile

A research on imaging of concentration of drug on the skin rash and normal skin tissue in patients with advanced pancreatic cancer treating with gemcitabine and erlotinib.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2016

At a glance

  • Drugs Erlotinib (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 03 Aug 2015 Planned number of patients changed from 5 to 11 as reported by University Hospital Medical Information Network - Japan.
    • 24 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top